Congenital Adrenal Hyperplasia clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
open to eligible people ages 18 years and up
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of treatment with crinecerfont. Duration of participation is approximately 20 months.
San Francisco, California and other locations
Last updated: